A powerful new class of drugs promises to change the management of heart disease for high-risk patients who struggle to…
Read More
FDA panel recommends new safety information on AstraZeneca’s Onglaza
AstraZeneca Plc’s diabetes drug Onglyza has a broadly acceptable cardiovascular safety profile but its label should include new information about…
Read MoreLilly’s psoriatic arthritis drug succeeds in late-stage study
Eli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients…
Read MoreFDA grants priority review to Roche’s leukemia drug
Swiss drugmaker Roche Holding AG said on Wednesday U.S. health regulators have granted priority review to its experimental leukemia treatment…
Read More
Statin side effects can often be overcome, study finds
Most people who stop taking cholesterol-lowering statins – because of side effects or for another reason – are able to…
Read More
FDA strengthens hepatitis B warning on 2 cancer drugs
U.S. health regulators have strengthened the warnings on two blood cancer drugs to reflect the risk that they may reactivate…
Read More
ADHD medications not tied to drug, alcohol abuse
Taking Ritalin and other drugs for attention-deficit/hyperactivity disorder (ADHD) doesn’t affect a child’s chances of trying or abusing alcohol and…
Read More
Indian-made medicines spark safety concerns
A number of Indian pharmaceutical companies are receiving criticism from the U.S. Food and Drug Administration (FDA) over increased lapses…
Read More
Hepatitis patients often ‘fall off’ the treatment path
Many people with hepatitis C end up not receiving adequate treatment, because they lose their way through the medical system…
Read More
WHO recommends naloxone to prevent 20,000 overdose deaths in U.S.
More than 20,000 deaths might be prevented every year in the United States alone if naloxone, used to counter drug…
Read More
